Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (Nasdaq: QSI) is a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Quantum-Si’s benchtop protein sequencing platform, chemistry kits, and data analysis tools are evolving over time.
Recent Quantum-Si news has highlighted product launches such as the V4 Sequencing Kit, which the company reports improves sequencing coverage through additional amino acid recognition, specialized enzymes, and enhanced algorithms. The company has also announced a Version 3 Library Preparation Kit designed for lower protein input and detection of low-abundance proteins, along with data analysis enhancements that unlock detection of additional amino acids and improve peptide alignment and protein inference.
Investors and researchers can use this page to track updates on Quantum-Si’s Proteus platform development, including prototype sequencing milestones, technology roadmap disclosures, and plans related to amino acid coverage, controlled cleavage chemistry, and post-translational modification methods. Financial news items, such as quarterly earnings releases, capital raising transactions, and lease or other material agreements disclosed via Form 8-K, also appear in this feed.
In addition, the news stream captures corporate governance and human capital updates, including inducement grants under the company’s 2023 Inducement Equity Incentive Plan, investor conference participation, and Investor & Analyst Day events. Bookmark this page to review Quantum-Si’s official press releases and regulatory news in one place, with a focus on developments that shape the company’s proteomics technology, commercialization efforts, and capital markets activity.
Detect, Inc. has secured an $8.1 million funding award from the National Institutes of Health (NIH) under the RADx initiative to advance its Detect™ Covid-19 Test. This test is currently pending FDA Emergency Use Authorization and promises PCR-quality results at home in approximately one hour. The funding will aid in scaling manufacturing to meet national demand. Designed for schools, businesses, and homes, the Detect Covid-19 Test targets all known Covid-19 variants, including Delta, enhancing accessible testing options in the U.S.
Quantum-Si Incorporated (NASDAQ: QSI) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. CEO John Stark and CFO Claudia Drayton will host a virtual fireside chat on September 29 from 1:20 to 1:50 PM EDT. Quantum-Si is focused on advancing proteomics through a novel semiconductor chip enabling next-generation protein sequencing. For more details, visit the Investor Relations section on their website.
Founded in 2013 by Dr. Jonathan Rothberg, Quantum-Si aims to transform drug discovery and diagnostics.
Quantum-Si (Nasdaq: QSI) announced its second-quarter 2021 financial results, highlighting a net loss of $35.7 million, up from a loss of $8.2 million in Q2 2020. Operating expenses surged to $32.2 million, a 292% increase year-over-year. Positive developments included the completion of a business combination with HighCape, adding over $511 million in cash, and the delivery of five early access systems to key thought leaders in the proteomics field. The company plans to build a 25,000 square foot facility in San Diego to enhance R&D and production capabilities.
Quantum-Si announced the rescheduling of its second quarter 2021 financial results conference call to August 16, 2021, post-market close. CEO John Stark and CFO Claudia Drayton will host the call at 4:30 p.m. ET to discuss financial results and a business update. The call will be available via webcast on the Investor Relations website. Quantum-Si, founded in 2013, focuses on semiconductor chip-based proteomics, leveraging technology aimed at advancing drug discovery and diagnostics beyond DNA sequencing.
Quantum-Si Incorporated plans to report its second quarter 2021 financial results on August 12, 2021, prior to market opening. CEO John Stark and CFO Claudia Drayton will hold a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. The call can be accessed via a live webcast on the company's Investor Relations website. Quantum-Si is focused on advancing proteomics through innovative semiconductor technology for protein sequencing.
Quantum-Si Incorporated has signed a lease with Phase 3 Real Estate Partners for a 25,586-square-foot facility in San Diego, CA. This site will enhance its product development and R&D capabilities, crucial for recruiting talent and commercial readiness in the proteomics market. Operations are anticipated to commence in Q3 2021. CEO John Stark emphasized the facility's role in scaling operations to meet the growing demand for protein sequencing technologies, which are expected to revolutionize drug discovery and diagnostics.
Quantum-Si Incorporated (Nasdaq: QSI) has successfully completed its business combination with HighCape Capital Acquisition Corp. (Nasdaq: CAPA), resulting in over $500 million for the development of its semiconductor chip-based protein sequencing technology. The combined company, now trading as Quantum-Si, aims to disrupt the $21 billion academic research and drug discovery market with its unique end-to-end solution. The company’s leadership includes experienced executives and it anticipates launching its products commercially in 2022.